Evidence map›Paper›PMID 35663963›Full record

ArticleFrontiers in immunology2022

Evaluating the Immune Response in Treatment-Naive Hospitalised Patients With Influenza and COVID-19.

Jelmer Legebeke, Jenny Lord, Rebekah Penrice-Randal, Andres F Vallejo, Stephen Poole, Nathan J Brendish, Xiaofeng Dong, Catherine Hartley, John W Holloway, Jane S Lucas and 10 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 2 countries.

Jelmer LegebekeSchool of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Jenny LordSchool of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Rebekah Penrice-RandalInstitute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, United Kingdom.
Andres F VallejoSchool of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Stephen PooleNational Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton National Health Service (NHS) Foundation Trust, Southampton, United Kingdom.
Nathan J BrendishNational Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton National Health Service (NHS) Foundation Trust, Southampton, United Kingdom.
Xiaofeng DongInstitute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, United Kingdom.
Catherine HartleyInstitute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, United Kingdom.
John W HollowaySchool of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Jane S LucasNational Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton National Health Service (NHS) Foundation Trust, Southampton, United Kingdom.
Anthony P WilliamsCancer Sciences Division, Faculty of Medicine, University Hospital Southampton, Southampton, United Kingdom.
Gabrielle WhewaySchool of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Fabio StrazzeriTopMD Precision Medicine Ltd, Southampton, United Kingdom.
Aaron GardnerTopMD Precision Medicine Ltd, Southampton, United Kingdom.
James P R SchofieldTopMD Precision Medicine Ltd, Southampton, United Kingdom.
Paul J SkippTopMD Precision Medicine Ltd, Southampton, United Kingdom.
Julian A HiscoxInstitute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, United Kingdom.
Marta E PolakSchool of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
Tristan W ClarkNational Institute for Health Research (NIHR) Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton National Health Service (NHS) Foundation Trust, Southampton, United Kingdom.
Diana BaralleSchool of Human Development and Health, Faculty of Medicine, University of Southampton, Southampton, United Kingdom.
University of Southampton · GBUniversity of Liverpool · GBNational Health Service · GBNIHR Southampton Biomedical Research Centre · GBUniversity Hospital Southampton NHS Foundation Trust · GBAgency for Science, Technology and Research · SGNational Institute for Health Research · GB

Funding

Department of Health 2016-09-061Department of Health NIHR-INF-0932Department of Health RP-2016-07-011Medical Research Council MR/N013840/1Wellcome Trust 109377/Z/15/Z
6 · The paper itself

Abstract

The worldwide COVID-19 pandemic has claimed millions of lives and has had a profound effect on global life. Understanding the body's immune response to SARS-CoV-2 infection is crucial in improving patient management and prognosis. In this study we compared influenza and SARS-CoV-2 infected patient cohorts to identify distinct blood transcript abundances and cellular composition to better understand the natural immune response associated with COVID-19, compared to another viral infection being influenza, and identify a prognostic signature of COVID-19 patient outcome. Clinical characteristics and peripheral blood were acquired upon hospital admission from two well characterised cohorts, a cohort of 88 patients infected with influenza and a cohort of 80 patients infected with SARS-CoV-2 during the first wave of the pandemic and prior to availability of COVID-19 treatments and vaccines. Gene transcript abundances, enriched pathways and cellular composition were compared between cohorts using RNA-seq. A genetic signature between COVID-19 survivors and non-survivors was assessed as a prognostic predictor of COVID-19 outcome. Contrasting immune responses were detected with an innate response elevated in influenza and an adaptive response elevated in COVID-19. Additionally ribosomal, mitochondrial oxidative stress and interferon signalling pathways differentiated the cohorts. An adaptive immune response was associated with COVID-19 survival, while an inflammatory response predicted death. A prognostic transcript signature, associated with circulating immunoglobulins, nucleosome assembly, cytokine production and T cell activation, was able to stratify COVID-19 patients likely to survive or die. This study provides a unique insight into the immune responses of treatment naïve patients with influenza or COVID-19. The comparison of immune response between COVID-19 survivors and non-survivors enables prognostication of COVID-19 patients and may suggest potential therapeutic strategies to improve survival.

Indexed as

COVID-19Influenza, HumanInfluenza VaccinesAdaptive ImmunityHumansPandemicsSARS-CoV-2Influenza VaccinesadaptivebloodCOVID-19immune responseinfluenzainnatesurvivaltranscriptome

Identifiers

PMID35663963
PMCPMC9160963
OpenAlexW4280638384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.